Mostafa Baranchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mostafa Baranchi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Maryam Esfahani
Hamedan University of Medical Sciences, Hamedan, Iran
3 shared publications- Mohammad Taghi Goodarzi
Department of Biochemistry, Islamic Azad University, Shahrood Branch, Shahrood, Iran
3 shared publications Ahmad Movahedian
Department of Clinical Biochemistry, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication
Latest Publications
- 1 July 2019
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (4) , 2477-2480
The implication of hepatokines in metabolic syndrome
- 1 July 2019
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (4) , 2477-2480
The implication of hepatokines in metabolic syndrome
- Open Access
- 23 January 2016
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 4 (1) , 1-33230
Irisin and Metabolic Disorders
Irisin and Metabolic Disorders
- 23 January 2016
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 4 (1) , 1-33230
Open AccessIrisin and Metabolic Disorders
Irisin and Metabolic Disorders
- Open Access
- 1 May 2015
- Vol. 18 (5) , 430-42
Adiponectin: an adipokine with protective features against metabolic syndrome.
Metabolic syndrome (MetS) as a collection of obesity-associated disorders is associated with inflammation, oxidative stress, pro-thrombotic state, elevated risk of developing cardiovascular disease and type 2 diabetes. Adiponectin is one of the most abundant peptide hormones derived from adipose tissue. This protein plays a major role in glucose and lipid metabolism and prevents development of vascular changes. Anti-oxidative and anti-inflammatory effects are the other features of adiponectin. Hypoadiponectinemia is associated with hypertension and pro-thrombotic state. In this review, we discuss the crucial role of adiponectin in prevention of metabolic syndrome considering its effects on the components of this syndrome. Pharmacological interventions and lifestyle modification may increase plasma adiponectin level or tissue sensitivity which seems to be a promising target for prevention and therapeutic approaches of MetS and related diseases.
- 1 May 2015
- Vol. 18 (5) , 430-42
Open AccessAdiponectin: an adipokine with protective features against metabolic syndrome.
Metabolic syndrome (MetS) as a collection of obesity-associated disorders is associated with inflammation, oxidative stress, pro-thrombotic state, elevated risk of developing cardiovascular disease and type 2 diabetes. Adiponectin is one of the most abundant peptide hormones derived from adipose tissue. This protein plays a major role in glucose and lipid metabolism and prevents development of vascular changes. Anti-oxidative and anti-inflammatory effects are the other features of adiponectin. Hypoadiponectinemia is associated with hypertension and pro-thrombotic state. In this review, we discuss the crucial role of adiponectin in prevention of metabolic syndrome considering its effects on the components of this syndrome. Pharmacological interventions and lifestyle modification may increase plasma adiponectin level or tissue sensitivity which seems to be a promising target for prevention and therapeutic approaches of MetS and related diseases.